Your browser is no longer supported. Please, upgrade your browser.
Settings
SLDB [NASD]
Solid Biosciences Inc.
Index- P/E- EPS (ttm)-1.73 Insider Own5.70% Shs Outstand63.23M Perf Week-9.94%
Market Cap496.65M Forward P/E- EPS next Y-1.18 Insider Trans343.87% Shs Float30.07M Perf Month-11.32%
Income-88.30M PEG- EPS next Q-0.32 Inst Own58.70% Short Float18.54% Perf Quarter-44.40%
Sales- P/S- EPS this Y41.60% Inst Trans18.61% Short Ratio3.34 Perf Half Y42.59%
Book/sh2.09 P/B2.21 EPS next Y16.30% ROA-102.80% Target Price- Perf Year84.06%
Cash/sh1.44 P/C3.21 EPS next 5Y- ROE-140.40% 52W Range1.93 - 11.58 Perf YTD-39.05%
Dividend- P/FCF- EPS past 5Y-53.40% ROI- 52W High-60.10% Beta0.99
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low139.38% ATR0.29
Employees70 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)35.65 Volatility6.15% 6.01%
OptionableYes Debt/Eq0.01 EPS Q/Q49.10% Profit Margin- Rel Volume0.26 Prev Close4.72
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.67M Price4.62
Recom2.70 SMA20-7.60% SMA50-26.79% SMA200-4.87% Volume439,163 Change-2.12%
Mar-16-21Upgrade SVB Leerink Mkt Perform → Outperform $3 → $15
Mar-09-21Initiated Barclays Overweight $13
Jan-08-21Upgrade Credit Suisse Underperform → Neutral $2 → $7
Jul-28-20Downgrade SVB Leerink Outperform → Mkt Perform
May-07-20Downgrade Evercore ISI Outperform → In-line
Oct-11-19Initiated Evercore ISI Outperform $22
Aug-29-19Downgrade Citigroup Neutral → Sell $6
Aug-19-19Upgrade SVB Leerink Mkt Perform → Outperform $8 → $15
Aug-16-19Upgrade Chardan Capital Markets Neutral → Buy $7.50 → $10
May-14-19Downgrade Goldman Neutral → Sell $5 → $4
May-14-19Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19Upgrade Citigroup Sell → Neutral $8
Feb-08-19Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18Initiated Citigroup Sell
Sep-06-18Initiated Credit Suisse Neutral $38
May-04-21 08:00AM  
Apr-20-21 07:30AM  
Apr-13-21 06:56AM  
Apr-12-21 07:30AM  
Mar-26-21 05:02PM  
Mar-25-21 07:30AM  
Mar-24-21 08:50AM  
Mar-23-21 04:22PM  
Mar-18-21 09:14PM  
Mar-17-21 04:20PM  
08:32AM  
06:35AM  
Mar-16-21 11:44AM  
11:16AM  
08:17AM  
08:07AM  
Mar-15-21 04:15PM  
02:30PM  
Mar-04-21 07:35AM  
07:30AM  
Feb-24-21 04:24PM  
Feb-17-21 07:30AM  
Jan-22-21 07:00AM  
Jan-08-21 07:23PM  
04:30PM  
11:57AM  
Jan-06-21 07:30AM  
Jan-04-21 09:34AM  
Dec-24-20 04:00PM  
Dec-11-20 02:36PM  
07:30AM  
Dec-09-20 07:51AM  
Dec-07-20 09:42AM  
Nov-05-20 07:00AM  
Nov-03-20 07:30AM  
Oct-28-20 03:03PM  
Oct-23-20 08:00AM  
Oct-09-20 08:54AM  
Oct-02-20 02:56PM  
07:30AM  
Oct-01-20 02:56PM  
11:02AM  
07:30AM  
Sep-11-20 02:45PM  
Sep-10-20 10:19AM  
Aug-21-20 03:00PM  
Jul-29-20 09:12PM  
Jul-28-20 12:50PM  
Jul-27-20 12:16PM  
Jul-24-20 05:50PM  
Jul-05-20 05:27PM  
Jun-18-20 07:00AM  
Jun-12-20 06:45AM  
May-29-20 08:35AM  
May-22-20 07:00AM  
May-14-20 07:00AM  
May-13-20 09:49AM  
May-11-20 03:03AM  
May-09-20 01:48PM  
May-07-20 07:22AM  
Apr-16-20 07:00AM  
Mar-12-20 07:00AM  
Jan-31-20 05:00AM  
Jan-22-20 11:48AM  
Jan-10-20 10:08AM  
Jan-09-20 08:00AM  
Dec-23-19 10:11AM  
Dec-19-19 06:08PM  
Dec-18-19 08:46AM  
08:38AM  
06:30AM  
Dec-16-19 08:52AM  
Dec-13-19 08:55AM  
Nov-20-19 01:28PM  
Nov-13-19 03:43PM  
Nov-12-19 05:51PM  
04:03PM  
10:56AM  
10:22AM  
10:15AM  
07:00AM  
06:45AM  
Oct-16-19 08:42AM  
Oct-02-19 07:30AM  
Sep-03-19 02:21PM  
Aug-29-19 11:38AM  
09:02AM  
Aug-27-19 07:23AM  
Aug-20-19 12:20PM  
12:02PM  
10:03AM  
Aug-19-19 03:17PM  
08:58AM  
Aug-16-19 12:15PM  
Aug-15-19 02:41PM  
Aug-14-19 07:25AM  
Aug-08-19 10:33AM  
Jul-26-19 07:25AM  
Jul-01-19 09:35AM  
09:21AM  
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLCDirectorMar 23Buy5.752,608,69514,999,99613,412,552Mar 23 05:19 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 19Buy5.752,206,68512,688,43910,916,567Mar 23 04:30 PM
Schneider Joel Solomon ZevChief Operating OfficerMar 12Sale8.8423,398206,920268,774Mar 15 04:05 PM
Morris Carl AshleyChief Scientific OfficerMar 12Sale8.8423,398206,947275,602Mar 15 04:05 PM
Ganot IlanCEO & PresidentFeb 12Sale7.664573,5013,026Feb 16 04:00 PM
Morris Carl AshleyChief Scientific OfficerJan 28Sale6.143,45921,238299,000Jan 29 04:00 PM
Ganot IlanCEO & PresidentJan 28Sale6.1410,71365,7761,199,821Jan 29 04:00 PM
Ziolkowski Jennifer LynnCFO, Treasurer & Asst. SecyJan 28Sale6.143,47321,327335,636Jan 29 04:00 PM
Schneider Joel Solomon ZevChief Technology OfficerJan 28Sale6.143,44321,145292,172Jan 29 04:00 PM
Ganot IlanCEO & PresidentAug 13Sale2.442997303,483Aug 14 04:07 PM
Morris Carl AshleyChief Scientific OfficerJul 28Sale2.423,5918,689290,959Jul 29 05:37 PM
Ziolkowski Jennifer LynnCFO, Treasurer & Asst. SecyJul 28Sale2.423,5918,687327,609Jul 29 05:33 PM
HERSCHA LYNETTEChief Legal OfficerJul 28Sale2.425,14112,438160,859Jul 29 05:28 PM
Ganot IlanCEO & PresidentJul 28Sale2.4211,12426,9101,148,007Jul 29 05:23 PM
Schneider Joel Solomon ZevChief Technology OfficerJul 28Sale2.424,0419,776284,115Jul 29 07:26 PM